The products contain a built-in electronic module that detects, records and stores data on inhaler events.
Patients treated with tocilizumab were 44% less likely to progress to mechanical ventilation or death compared with placebo.
The ongoing randomized, double-blind, placebo-controlled BLAZE-1 trial is investigating the treatment in adult patients with mild to moderate COVID-19 symptoms who are not currently hospitalized.
The ACTT-2 study began on May 8 and included more than 1000 patients.
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist.
The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis.
The double-blind, placebo-controlled studies, COUGH-1 and COUGH-2, included 730 and 1314 adult patients with refractory or unexplained chronic cough for at least 1 year, respectively.
The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.